Why the study?
To assess levels of MMP-9 and MPO, as well as MPO gene polymorphisms, in patients with CAD living in the Elazığ region.
Plasma MPO levels are significantly associated with coronary artery disease, suggesting potential utility as a biomarker, whereas MMP-9 levels and MPO G-463A gene polymorphism did not show significant associations in this cohort.
Objective: Coronary artery disease(CAD) patients living in Elazığ region is to assess the levels of matrix metalloproteinase-9(MMP-9) and myeloperoxidase(MPO), polymorphisms MPO gene. Research Design and Methods: Eighty-eight patients with angiographically diagnosed coronary artery disease between the ages of 18-80 who applied to Department of Cardiology, Faculty of Medicine, Firat University were enrolled in this study. MPO, MMP-9 levels in plasma samples of individuals were determined by enzyme-linked immuno sorbent assay (ELISA) according to the kit procedure. MPO polymorphism was studied using the PCR-RFLP technique. Results: When plasma MPO and MMP-9 levels were compared in the control and CAD groups; MPO levels were statistically significant (p <0.05). MMP-9 levels were not statistically significant. MPO gene polymorphism was not found statistically significant in CAD. Conclusion: MPO gene polymorphism is thought to be associated with greater population populations in CAD and may be used in the future as a biomarker for plasma MPO enzyme levels in CAD. Key words: MPO, coronary artery disease, MMP-9 DOI: 10.7176/JHMN/83-02
No takes yet. Share an insight, caveat, or question.
Döğüş et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: